IBI301 plus CHOP + Rituximab plus CHOP
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diffuse, Large B-Cell, Lymphoma
Conditions
Diffuse, Large B-Cell, Lymphoma
Trial Timeline
Aug 22, 2016 → Dec 26, 2019
NCT ID
NCT02867566About IBI301 plus CHOP + Rituximab plus CHOP
IBI301 plus CHOP + Rituximab plus CHOP is a phase 3 stage product being developed by Innovent Biologics for Diffuse, Large B-Cell, Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02867566. Target conditions include Diffuse, Large B-Cell, Lymphoma.
What happened to similar drugs?
1 of 20 similar drugs in Diffuse, Large B-Cell, Lymphoma were approved
Approved (1) Terminated (4) Active (15)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02867566 | Phase 3 | Completed |
Competing Products
20 competing products in Diffuse, Large B-Cell, Lymphoma